针对前列腺特异性膜抗原的抗体J591的α-标记:来自美国某学术机构第一个专门生产实验室的技术和考虑

IF 1 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Journal of nuclear medicine technology Pub Date : 2023-09-01 DOI:10.2967/jnmt.122.265166
Kritika Subramanian, Judith Stangl-Kremser, Lady Sawoszczyk, Vasilios Avlonitis, Andrew Gernerd, Kyla Nixon, Michael Zgaljardic, Scott Tagawa, Neil Bander, Joseph R Osborne
{"title":"针对前列腺特异性膜抗原的抗体J591的α-标记:来自美国某学术机构第一个专门生产实验室的技术和考虑","authors":"Kritika Subramanian,&nbsp;Judith Stangl-Kremser,&nbsp;Lady Sawoszczyk,&nbsp;Vasilios Avlonitis,&nbsp;Andrew Gernerd,&nbsp;Kyla Nixon,&nbsp;Michael Zgaljardic,&nbsp;Scott Tagawa,&nbsp;Neil Bander,&nbsp;Joseph R Osborne","doi":"10.2967/jnmt.122.265166","DOIUrl":null,"url":null,"abstract":"<p><p>The protein expression of the prostate-specific membrane antigen correlates with unfavorable or aggressive histologic features of prostate cancer, resulting in use as a diagnostic PET imaging radiotracer and therapeutic target. Here, we discuss the methods to develop <sup>225</sup>Ac-DOTA-J591, an α-labeled compound targeting an extracellular epitope of prostate-specific membrane antigen, which is currently being studied in early clinical trials. In addition, we review quality control, radiation safety measures, and clinical considerations before administration of this radioimmunotherapeutic agent.</p>","PeriodicalId":16548,"journal":{"name":"Journal of nuclear medicine technology","volume":"51 3","pages":"215-219"},"PeriodicalIF":1.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"α-Labeling of J591, an Antibody Targeting Prostate-Specific Membrane Antigen: The Technique and Considerations from the First Dedicated Production Lab at an Academic Institution in the United States.\",\"authors\":\"Kritika Subramanian,&nbsp;Judith Stangl-Kremser,&nbsp;Lady Sawoszczyk,&nbsp;Vasilios Avlonitis,&nbsp;Andrew Gernerd,&nbsp;Kyla Nixon,&nbsp;Michael Zgaljardic,&nbsp;Scott Tagawa,&nbsp;Neil Bander,&nbsp;Joseph R Osborne\",\"doi\":\"10.2967/jnmt.122.265166\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The protein expression of the prostate-specific membrane antigen correlates with unfavorable or aggressive histologic features of prostate cancer, resulting in use as a diagnostic PET imaging radiotracer and therapeutic target. Here, we discuss the methods to develop <sup>225</sup>Ac-DOTA-J591, an α-labeled compound targeting an extracellular epitope of prostate-specific membrane antigen, which is currently being studied in early clinical trials. In addition, we review quality control, radiation safety measures, and clinical considerations before administration of this radioimmunotherapeutic agent.</p>\",\"PeriodicalId\":16548,\"journal\":{\"name\":\"Journal of nuclear medicine technology\",\"volume\":\"51 3\",\"pages\":\"215-219\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of nuclear medicine technology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2967/jnmt.122.265166\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of nuclear medicine technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2967/jnmt.122.265166","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

摘要

前列腺特异性膜抗原的蛋白表达与前列腺癌的不利或侵袭性组织学特征相关,因此被用作诊断性PET成像放射性示踪剂和治疗靶点。在此,我们讨论了开发225Ac-DOTA-J591的方法,这是一种α-标记的靶向前列腺特异性膜抗原细胞外表位的化合物,目前正在进行早期临床试验研究。此外,我们回顾了质量控制,辐射安全措施,以及在使用这种放射免疫治疗剂之前的临床考虑。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
α-Labeling of J591, an Antibody Targeting Prostate-Specific Membrane Antigen: The Technique and Considerations from the First Dedicated Production Lab at an Academic Institution in the United States.

The protein expression of the prostate-specific membrane antigen correlates with unfavorable or aggressive histologic features of prostate cancer, resulting in use as a diagnostic PET imaging radiotracer and therapeutic target. Here, we discuss the methods to develop 225Ac-DOTA-J591, an α-labeled compound targeting an extracellular epitope of prostate-specific membrane antigen, which is currently being studied in early clinical trials. In addition, we review quality control, radiation safety measures, and clinical considerations before administration of this radioimmunotherapeutic agent.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of nuclear medicine technology
Journal of nuclear medicine technology RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-
CiteScore
1.90
自引率
15.40%
发文量
57
期刊最新文献
Amyloid Imaging Update: How the Amyloid Landscape Is Changing in Light of the Recent Food and Drug Administration Approval of Antiamyloid Therapeutics. Brain Imaging-PET: Tau. Decoding the Jargon: Understanding the Nomenclature of Clinical Education. Delivery Methods of Radiopharmaceuticals: Exploring Global Strategies to Minimize Occupational Radiation Exposure. SPECT Views for Cardiac Amyloidosis Imaging.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1